Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma

Clinical Cancer Research

Volumn 24, Issue 6, 2018, Pages 1296-1304

  Huang, Jing ^a,b   Xu, Binghe ^a   Mo, Hongnan ^a   Zhang, Weilong ^a   Chen, Xuelian ^a   Wu, Dawei ^a   Qu, Dong ^a   Wang, Xingyuan ^a   Lan, Bo ^a   Yang, Beibei ^a   Wang, Pei ^a   Zhang, Hongtu ^b   Yang, Qing ^c   Jiao, Yuchen ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL   (China)

^c Jiangsu Hengrui Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; SHR 1210; UNCLASSIFIED DRUG; CAMRELIZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CAPILLARY HEMANGIOMA; CHINA; COHORT ANALYSIS; DIARRHEA; DISEASE BURDEN; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOTHYROIDISM; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; SOMATIC MUTATION; TREATMENT RESPONSE; WHOLE EXOME SEQUENCING; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; ESOPHAGUS TUMOR; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 85044137395     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-2439     Document Type: Article

References (22)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349: 2241–52.
3. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw 2015;13:194–227.
4. Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y, Muto M. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology 2015;149:1700–15.
5. Huang J, Zhou Y, Zhang H, Qu T, Mao Y, Zhu H, et al. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol 2013;30:343.
6. Huang J, Fan Q, Lu P, Ying J, Ma C, Liu W, et al. Icotinib in patients with pretreated advanced esophageal squamous cell carcinoma with EGFR overexpression or EGFR gene amplification: a single-arm, multicenter phase 2 study. J Thorac Oncol 2016;11:910–7.
7. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320–30.
8. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–33.
9. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803–13.
10. Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol 2017;18:631–9.
11. Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Saraf S, Koshiji M, et al. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). J Clin Oncol 2016;34:7-.
12. Zhang W, He H, Zang M, Wu Q, Zhao H, Lu LL, et al. Genetic features of aflatoxin-associated hepatocellular carcinomas. Gastroenterology 2017; 153:249–262.
13. Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled rando-mised trial. Lancet Oncol 2014;15:894–904.
14. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717–26.
15. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018–28.
16. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
17. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvi-ronment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064–74.
18. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–35.
19. Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 2014;46:1097–102.
20. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014;509:91–5.
21. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–20.
22. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189–99.